China officially approved the widespread use of vaccines produced by Sinovac Biotech


The move marks the Sinovac Biotech Covid-19 vaccine as the second most widely used vaccine in the world’s most populous country.

VThe China National Health Products Administration’s approval of the two-dose vaccine regimen is based on the results of two-month external terminal clinical trials. Photo: Shutterstock

Previously, in December 2020, Chinese authorities approved the first widespread use of Covid-19-resistant vaccine cooperated by a research institute in Beijing and China National Pharmaceutical Corporation (Sinopharm). manufacturing.

Both of these vaccines, as well as the third one from Sinopharm, have been used in China’s vaccination program of more than 31 million doses, mainly targeting high-risk populations. .

The fourth vaccine is made by another Chinese vaccine company, CanSino Biologics, and is being used to inject soldiers.

Sinovac said in a recent press release that Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos have issued an emergency license to use the Covid-19 resistant vaccine by Sinovac Life Sciences – a subsidiary. based in Beijing by Sinovac Biotech.

The approval of the Chinese National Health Product Authority’s two-dose vaccination regimen is based on results of two-month external final-stage clinical trials, but no final analytical data are available. , Sinovac added.

The Sinovac Life Sciences Company says it is expected to mass produce more than 1 billion doses of Covid-19-resistant vaccine a year by February 2021. In addition, the Sinovac side is also improving its capacity to provide vaccines with vials and syringes because this process is hindering the unit’s capacity to produce vaccines. Sinovac has also outsourced the completion of vaccine products to foreign partners.

The country planned to provide 10 million doses of vaccine to the Covid-19 COVAX vaccine program, a global vaccine-sharing initiative run by the Health Organization, Reuters reported as saying. World (WHO) promoted and Sinovac, Sinopharm, and CanSino signed up to participate.

Results of phase I and II vaccine trials in China showed that the vaccines tested could safely trigger an immune response in vaccinated elders. These vaccines are also currently being tested in subjects aged 3 to 17 years.

However, Sinovac warns that data on the protective efficacy of Covid-19-resistant vaccines in people 60 years of age and older are “limited”. In addition, Sinovac also recommended that when the relevant authorities use their vaccine, it is important to evaluate vaccine use based on the health status and exposure risk of the above age group.

Design by NewsLax